At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 903 enrolled
Drug / intervention
CNTO 1275 45 mg +2 moredrug
Likely dose
CNTO 1275 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating CNTO 1275 45 mg, CNTO 1275 90 mg, and 1 other intervention for Psoriasis. Completed, enrolled 903 participants.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMar 2007
Primary CompletionJan 2008
Study CompletionJan 2009
TodayJul 2026
First PostedMar 30, 2007
Enrollment StartMar 1, 2007
Primary CompletionJan 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.3 years ago
Interventions
CNTO 1275 45 mgdrug
Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
CNTO 1275 90 mgdrug
Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
Etanercept 50 mgdrug
Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous